Galena Biopharma fourth-quarter loss narrows on a YOY basis
- Author: Zachary Reyes Mar 30, 2017,
Mar 30, 2017, 16:40
The Stock opened its session at $0.56 and closed at $0.55 by showing decrease of -3.51 percent. The analysts believe that the company stock price could grow as high as $8. It has been assigned a low target price of $23 and a high target price of $35. Different analysts and financial institutions use various valuation methods and consider different economic forces when deciding on a price target.
05/12/2015 - Galena Biopharma, Inc. was upgraded to "buy" by analysts at Zacks.
Average price target for Galena Biopharma, Inc. The price swings are an indicator of stock price volatility, and potential takeover rumors.
If we look at stock performance in last active day trading, we see that stock has moved advanced 4.83% to end the day at $3.69. Additionally, "buy, hold and sell" recommendation meanings are not as transparent as they first seem; a plethora of terms and variance in meanings exist behind the curtain and serve to muddy the waters. Galena Biopharma, Inc., formally known as RXi Pharmaceuticals Corporation, is based in Portland, Oregon. (NASDAQ: GALE) can be downloaded free of charge at Research Driven Investing. The company reported $-0.17 EPS for the quarter, beating the analyst consensus estimate by $ 0.35.
Galena Biopharma, Inc is a biopharmaceutical company.
Glancing over stock's performance with EPS trend, the current quarter estimates trends for EPS by pool of analysts was $0.01 and for one month ago was $0.01, as Q1 2017 Trends estimate stands at $0.13, according to WSJ analytic reports. The company has Beta Value of 1.56 and ATR value of 0.09. The analyst recommendations from a month ago are 18 Buy, 1 Overweight, 0 Sell, 6 Hold and 0 Underweight. The high and low revenue estimates for the current quarter are $0 and $0, respectively. The most expectant earnings per share estimate of the stock is set at $-2.27 while the conservative estimates kept at $-2.54 over the current year. The stock's 50 day moving average price is $0.86 and its 200 day moving average price is $1.21. The difference between Actual EPS and Estimated EPS was 0.3 Percent. The company posted a positive surprise factor of 14.29% by -0.20.
Galena Biopharma, Inc. (NASDAQ:GALE) has a market capitalization of 17.67 Million.
Insider Trades for Galena Biopharma, Inc. show that the latest trade was made on 7 Feb 2017 where Hudson Bay Capital Management, L.P., the Beneficial Owner of More than 10% Class completed a transaction type "Sell" in which 2363441 shares were traded at a price of $0.84. The stock touched its high share price of $4.75 on Nov 21, 2016 and the stock also touched its Lowest price in the last 52-weeks of trading on Nov 9, 2016 as $0.16. Tracking the stock price in relation to moving averages as well as highs and lows for the year might assist with evaluating future stock performance.
The stock has Return on Assets (ROA) of -51.1 percent.
The stock is now showing YTD performance of -68.04 Percent. The performance for Year to Date (YTD) is -71.71%.
01/22/2016 - Galena Biopharma, Inc. had its "outperform" rating reiterated by analysts at Oppenheimer. (NASDAQ:GALE) is 0.47. The Average Volume (3 months) is 2.4 Million.